CAMBRIDGE, Mass., March 6,
2024 /PRNewswire/ -- Blueprint Medicines Corporation
(Nasdaq: BPMC), today announced that, effective March 1, 2024, the Compensation Committee of
Blueprint Medicines' Board of Directors granted non-qualified stock
options to purchase an aggregate of 2,615 shares of its common
stock and an aggregate of 1,307 restricted stock units (RSUs) to
three new employees under Blueprint Medicines' 2020 Inducement
Plan.
The 2020 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously an employee or
non-employee director of Blueprint Medicines, as an inducement
material to such individual's entering into employment with
Blueprint Medicines, pursuant to Rule 5635(c)(4) of the Nasdaq
Listing Rules.
The options have an exercise price of $95.12 per share, which is equal to the closing
price of Blueprint Medicines' common stock on March 1, 2024. Each option will vest as to 25% of
the shares underlying such option on the first anniversary of the
grant date and as to an additional 1/48th of the shares underlying
the option monthly thereafter, in each case, subject to each
such employee's continued employment on each vesting date. Each RSU
will vest as to 25% of the shares underlying the RSU award on the
first anniversary of the grant date and as to an additional 25% of
the shares underlying the RSU award annually thereafter, subject to
each such employee's continued employment on each vesting date. The
options and RSUs are subject to the terms and conditions of
Blueprint Medicines' 2020 Inducement Plan, and the terms and
conditions of the stock option and RSU agreement covering the
grant.
About Blueprint Medicines
Blueprint Medicines is
a fully integrated, commercial-stage, global biopharmaceutical
company that invents life-changing medicines in two core, strategic
areas of allergy/inflammation and oncology/hematology. We pursue
discovery, development, and commercialization of therapies that
potently and selectively target known drivers of disease, with
focused investment in therapeutic areas where we can leverage our
core expertise and business infrastructure to bring scale to our
science. We are bringing AYVAKIT®/AYVAKYT® (avapritinib) to people
living with systemic mastocytosis (SM) in
the U.S. and Europe. Additionally, we have a
pipeline of research and development programs that range from early
science to advanced clinical trials in mast cell-mediated diseases,
including SM and chronic urticaria, breast cancer, and other solid
tumors vulnerable to CDK2 inhibition. For more information,
visit www.BlueprintMedicines.com and follow us
on X (formerly Twitter; @BlueprintMeds)
and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302081437.html
SOURCE Blueprint Medicines Corporation